This Master's Degree will give you during 12 months the keys, techniques and essential tools of the professional profile Medical Affairs” 

As well as high turnover figures and the generation of direct and indirect wealth, the pharmaceutical industry currently has a great impact on the welfare state. In this scenario, the Medical Affairs,  department has gained vital importance in recent years, where professionals must carry out an exquisite task of providing information on the latest developments in treatments with a medical approach, within a framework of generalized sustainability.

The numerous studies to which drugs are subjected, which must be interpreted and communicated to healthcare personnel for their correct use and sale, mean that the staff of the medical department or  Medical Affairs must also possess excellent technical and scientific skills and knowledge in order to achieve a relationship of trust and credibility with opinion leaders and other healthcare professionals. Therefore, given that these profiles are increasingly in demand by companies and at the same time that the configuration of these areas as strategic pillars of the pharmaceutical industry, together with R&D and sales, is becoming more relevant, TECH has designed this Master's Degree in Medical Affairs.

A program taught exclusively online, which will take the medical specialist over 1,500 teaching hours to delve into the techniques most commonly used by professionals who make up the Medical Affairs, department, statistical tools, the most effective methods in literature searches, scientific evidence, necessary to conduct drug research studies.

All this will be possible thanks to innovative teaching resources (video summaries,  in focus) videos), essential readings, case simulations, to which you will have access 24 hours a day, from any electronic device with an Internet connection.

This academic institution thus provides a flexible university degree, which can be comfortably studied by the professional. With no classroom attendance or fixed class schedules, students also have the possibility of distributing the course load according to their needs, making this online program an excellent opportunity for those who wish to combine the most demanding responsibilities with a Master's Degree.

Access 24 hours a day, 7 days a week to the multimedia resource library of this quality university program” 

This Master's Degree in Medical Affairs contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of case studies presented by experts in medicine and the pharmaceutical industry
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

A flexible academic option that adapts to you. No presence, no fixed classes, you only need a computer with internet connection to visualize the syllabus” 

The program’s teaching staff includes professionals from sector who contribute their work experience to this program, as well as renowned specialists from leading societies and prestigious universities. 

Its multimedia content, developed with the latest educational technology, will allow the professional a situated and contextual learning, that is, a simulated environment that will provide an immersive education programmed to prepare in real situations. 

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the academic year For this purpose, the student will be assisted by an innovative interactive video system created by renowned and experienced experts. 

With this program you will be able to delve into pharmacoeconomics and the economic evaluation of a drug through multimedia resources"

With this university program, you will be aware of the future of clinical trial research and the new approach to clinical trials”

The specialists who enter this program will obtain an update of their knowledge through a study plan configured to offer the most relevant and innovative information in the field of Medical Affairs. For this purpose, it has a syllabus divided into 10 modules that will introduce you to the raison d'être of the medical department in pharmaceutical companies, pharmacoeconomics, digital transformation in this industry or professional competencies for working in Medical Affairs. Likewise, the multimedia resources and the Relearning  system will lead the professional to enter in a much more dynamic and attractive way through the content of this Master's Degree. 

A curriculum that will take you deep into the latest techniques, digital tools and resources used in Medical Affairs” 

Module 1. The drug access environment in the 21st century

1.1. Role of the pharmaceutical industry in the provision of health care in health systems

1.1.1. Core competencies that a public health administration should have
1.1.2. Constantly changing health care models Emergence of new technologies, need for greater efficiency and sustainability
1.1.3. Innovative industry challenges for the development of innovative treatments The benefits of public-private collaboration in R&D
1.1.4. Challenges of the Pharmaceutical Industry in market access The benefits Public-Private Partnership Models

1.2. Current challenges and pricing and reimbursement

1.2.1. Challenges for the NHS Increased life expectancy-timeliness more sophisticated drugs uncertainty management
1.2.2. Pricing and financing procedure. Ministries of health, price commissions, pharmaceutical benefit advisory committees
1.2.3. Drug pricing and pricing policies
1.2.4. Current panorama of innovative drug financing. Uncertainty management
1.2.5. Models of access to innovation and management of clinical and budgetary uncertainty by the pharmaceutical industry

1.3. Stakeholders  of the pharmaceutical industry I

1.3.1. The different Stakeholders and their interests
1.3.2. Relationship between industry and health care managers: public and private spheres
1.3.3. Relationship between industry and public administrations
1.3.4. Relationships with health care professionals

1.4. Stakeholders  of the pharmaceutical industry II

1.4.1. Patient relations as a key stakeholder in the health care environment
1.4.2. Relations with other  Stakeholders: scientific societies, professional associations, Lobby and influence groups, political institutions, media

1.5. Types of Drugs Innovative pharmaceuticals

1.5.1. Types of drugs: innovators, generics and biosimilars
1.5.2. Market introduction of an innovative drug. Importance of a good identification according to the drug type
1.5.3. Approximation Strategy and Match with different Customers
1.5.4. Rare diseases and orphan drugs
1.5.5. Personalized Medicine

1.6. Types of Drugs Generic and biosimilar drugs

1.6.1. Differences between generics, biosimilars and originator drugs
1.6.2. Role of generics and biosimilars in the pharmaceutical market
1.6.3. Approximation Strategy and Match with different Customers
1.6.4. Forms of contracting, tenders and central purchasing office
1.6.5. Substitution, interchangeability of generic drugs

1.7. Business ethics and bioethics

1.7.1. Internal compliance policies of the pharmaceutical company
1.7.2. Transparency of the pharmaceutical industry's interrelationships

1.8. Transparencia de las interrelaciones de la industria farmacéutica

1.8.1. New diseases with unmet medical needs
1.8.2. Establish the phases involved in the development of a new drug. Well-defined investment strategies
1.8.3. Need to implement new technologies in the research, development and production processes of the innovative drug
1.8.4. Competitor entry and shortening of the drug life cycle
1.8.5. Sustainability, equity and information management systems

1.9. Water in the Pharmaceutical Industry

1.9.1. Personalized and Precision Medicine
1.9.2. Role of patients in decision making
1.9.3. The Transparency Commitment
1.9.4. Basis for public-private partnerships

1.10. From universal access to innovative drugs to cost control

1.10.1. Evolution of access to innovative medicines
1.10.2. The Cost of Medication
1.10.3. Clinical Relevance
1.10.4. The Makers (F) Map
1.10.5. Finding the right balance

Module 2. Medical affairs department

2.1. What is the medical affairs department?

2.1.1. History of the Medical Affairs  department and its evolution in pharmaceutical companies
2.1.2. Objective and functions of the department
2.1.3. General department structure in different companies

2.2. Medical affairs department in pharmaceutical and biotech companies Biotechs

2.2.1. Relationship of medical affairs with commercial departments
2.2.2. Relationship of medical issues with the Market Access Department
2.2.3. Relationship of medical issues with the Regulatory Department
2.2.4. Relationship of medical issues with the Research and Clinical Trials Department and Clinical Trials
2.2.5. Product Life Cycle of issues

2.3. Product Life Cycle medical

2.3.1. La Product Life Cycle Strategies
2.3.2. Launching strategies

2.4. Medical plan and product plan

2.4.1. Definition of medical plan and product plan
2.4.2. Product plan structure: strategic and action plan
2.4.3. Medical Affairs and Medical Societies:  support for health care professionals through societies

2.5. Roles in the Medical Affairs Department: the Medical Advisor

2.5.1. Medical Advisor: functions: design of medical product strategy
2.5.2. Management of medical projects and Phase IV studies
2.5.3. Medical project finance

2.6. Roles in the medical affairs department: the MSL

2.6.1. MSL functions: medical communication and interlocutors
2.6.2. Implementation of medical projects and territorial management
2.6.3. MSL Skills 
2.6.4. Time management and prioritization

2.7. Medical communication and Insights gathering

2.7.1. High-impact F2F communication
2.7.2. Tailoring communication to profile and Insightsbased communication
2.7.3. Management of medical requests and negotiation

2.8. Communication Plan

2.8.1. Media and omni-channel plan
2.8.2. Communication at congresses
2.8.3. Integration of the communication plan in the medical plan

2.9. RWE and Phase IV studies

2.9.1. RWE and Phase IV study design
2.9.2. Medical plan integration
2.9.3. Estudios/ensayos iniciados por investigadores y colaboraciones de investigación
2.9.4. Collection and Measuring of Results

2.10. Compliance in the medical affairs department

2.10.1. Definition of promotion
2.10.2. Definition of  On Label/Off Label
2.10.3. Differences between commercial department and medical affairs
2.10.4. Integrity at Work

Module 3. What is the reason for a Medical Affairs department? Its reason for being

3.1. Medical Affairs: the new role of the pharmaceutical industry

3.1.1. From how it was to how it is now
3.1.2. From Industries to Science
3.1.3. Beyond clinical trials: generating evidence

3.2. Expectations for the future of Medical Affairs departments

3.2.1. Relationship with public institutions, physicians and patients
3.2.2. “Win-Win” or "all together" as the future
3.2.3. Coordination of Clinical Trials
3.2.4. Research Project Design
3.2.5. Patient as a source of success

3.3. Commitment of the pharmaceutical industry

3.3.1. In promoting the well-being of patients with ethical criteria of professionalism 
3.3.2. In generating and maintaining confidence in the prescribing of medicines
3.3.3. Objective: to contribute to the quality of care in a sustainable manner

3.4. Ability to measure the impact of what we do

3.4.1. Training and information
3.4.2. Correct analysis of scientific and non-scientific information
3.4.3. Evaluating whether or not a treatment works for our patients
3.4.4. Know whether the strategic decisions we have made are having the desired impact the desired impact
3.4.5. Genuine concern for patients

3.5. Development of a health sciences professional in the pharmaceutical industry

3.5.1. Design of a Training Plan: what to study?
3.5.2. Self-training
3.5.3. Team profile: innovation, leadership, etc
3.5.4. Development plans within the role
3.5.5. Career Plans

3.6. Research with Drugs for Human Use

3.6.1. Definition, justification and objectives of research with drugs for human use
3.6.2. Drug Research Ethics Types
3.6.3. Ethical Foundations Standards of Good Clinical Practice
3.6.4. Agents involved in clinical research: sponsor, investigator, monitor, patient

3.7. Clinical Trials Phases I

3.7.1. Phase 0 Clinical Studies
3.7.2. Phase I Clinical Studies: Is the treatment safe?

3.8. Clinical Trials Phases II

3.8.1. Phase II Clinical Studies I: Is the treatment effective?
3.8.2. Phase III Clinical Studies: Is the new treatment under study better than the conventional treatment?
3.8.3. Phase IV Clinical Studies: What else do I need to know?

3.9. Clinical Trials Methodology

3.9.1. Clinical Trial Design
3.9.2. Clinical Trial Planning
3.9.3. Stages in the Development of Clinical Trials
3.9.4. Monitoring: follow-up and control. The Importance of Quality
3.9.5. Data Management Obtaining results
3.9.6. Risk-based monitoring
3.9.7. Decentralized studies

3.10. The future of clinical trial research

3.10.1. Clinical Trials Evolution
3.10.2. From clinical evidence to regulatory need
3.10.3. From clinical trial data to price approval: what more data is needed?
3.10.4. Patient Monitoring
3.10.5. The cooperative environment for evidence generation

Module 4. Market Access, Health Economics & Outcomes Research

4.1. Introduction to pharmacoeconomics and economic evaluation of pharmaceuticals

4.1.1. Basic Concepts
4.1.2. Why and for what purpose are they used in health decision making?
4.1.3. Opportunity Cost
4.1.4. Consumption of health and non-health resources in pharmacoeconomics studies (types of costs)
4.1.5. Measurement and estimation of health (Outcomes)
4.1.6. QALY: concept and methods for its calculation

4.2. Types of full pharmacoeconomic analyses most commonly used in the economic evaluation of drugs

4.2.1. Cost Analysis and Allocation
4.2.2. Cost-effectiveness and cost-utility analysis
4.2.3. Cost-Benefit Analysis
4.2.4. Concept of the incremental cost per additional unit of health benefit
4.2.5. Interpretation of the results of economic evaluations and decision rules

4.3. Types of partial pharmacoeconomic analysis

4.3.1. Cost of illness and cost and consequence studies
4.3.2. Budget Impact Analysis: what is it, how is it done and what is it for in drug pricing and financing decisions
4.3.3. Other decision support analyses NNT, MCDA

4.4. Current importance of health outcome measurement

4.4.1. Patient-reported health outcomes PROs and PREs in the context of clinical research
4.4.2. Concept, definition and introduction to measurement with health scales
4.4.3. What can be measured and with what instruments?
4.4.4. The EQ-5D SF-36 Questionnaire

4.5. Critical review of published economic evaluations in the literature

4.5.1. Application of existing list-guides
4.5.2. Review of international guidelines and recommendations for designing and conducting and conducting economic evaluations
4.5.3. Systematic reviews and meta-analyses of published economic evaluations

4.6. Market Access

4.6.1. Environmental. Health Systems: Bismarck Model and Beveridge Model
4.6.2. Equity/access
4.6.3. Challenges of Health Systems

4.7. Arrival of the drug to the patient

4.7.1. Price negotiation and financing process
4.7.2. Most common barriers to drug financing/pricing
4.7.3. Price erosion over the life of the medicine

4.8. What is market access?

4.8.1. Introduction
4.8.2. How to Create a Strategies for the Access?
4.8.3. Value proposition and strategic market access dossier for a new drug of a new drug
4.8.4. Definition and implementation of the access plan for a new therapeutic option

4.9. Different drug financing models

4.9.1. Financial models (price-volume agreements, expenditure ceilings, etc.)
4.9.2. Clinical outcome-based models (risk-sharing programs, etc.) 
4.9.3. Patient access schemes
4.9.4. Other ways to increase market access for new therapeutic options

4.10. HTA evaluation (health technology assessment)

4.10.1. Different methodologies in different countries
4.10.2. Basic rules that an HTA regulation must have
4.10.3. Current Situation and Future Development

Module 5. Vision from hospital pharmacy, clinical research and new tools to investigate and new tools for research

5.1. Structure and Function of the Hospital Pharmacy. Service

5.1.1. Structure and Organization of the Hospital Pharmacy. Service
5.1.2. Objectives and functions of a hospital pharmacy service
5.1.3. Prioritization in the development of the functions of a pharmacy service
5.1.4. Portfolio of services and areas of work
5.1.5. Resources. Teamwork

5.2. Drug research in the hospital: hospital pharmacy vision

5.2.1. Clinical Research and Trials
5.2.2. Medications used and participants in a clinical trial
5.2.3. Functions of the Pharmacy/Medicine Management System of the drug of the clinical trial
5.2.4. Financing of studies and contracts

5.3. Role of the pharmacist in access to and positioning of medicines in the hospital in the hospital

5.3.1. Authorization and marketing of medicines
5.3.2. Drug selection: drug selection
5.3.3. Selection of Evidence-Based Medicine
5.3.4. Therapeutic Positioning Reports

5.4. Pharmacotherapeutic monitoring: health outcomes and telepharmacy

5.4.1. Patient-perceived health outcomes (PROMs): What Are They? and how to measure them?
5.4.2. Health outcomes patient reported experience (PREMs): What are they and how to measurement them?
5.4.3. APN Clinical Practice Application
5.4.4. Telepharmacy towards a new patient follow-up model

5.5. Safety in the Use of ICTs in the At Hospital

5.5.1. The Importance of Security/Safety
5.5.2. Medication errors
5.5.3. Risk Management and Notification Systems Incident
5.5.4. Prevention of Medication Errors

5.6. Advantages of Vaccines in General:

5.6.1. Why are vaccines necessary?
5.6.2. Impact of Vaccines on Health
5.6.3. Vaccine Safety
5.6.4. Phases in the Development of vaccines are

5.7. Vaccination in Risk Groups

5.7.1. Risk Groups
5.7.2. Risk Situations
5.7.3. Vaccination highlights: What's new?

5.8. Hospital research support platform

5.8.1. State of the art software as an aid to research
5.8.2. Website Architecture
5.8.3. Regulatory requirements

5.9. Healthy data

5.9.1. The logistics of sound data
5.9.2. OSHMS Certification

5.10. New technology applied to research

5.10.1. La New Technologies in Data Visualization
5.10.2. New technology in data analysis
5.10.3. New technology in the prediction of research data

Module 6. New value projects of the pharmaceutical industry. Digital transformation in Medical Medical Affairs

6.1. Change management, value-added services in strategic projects

6.1.1. Time of change or change of era
6.1.2. Why do changes fail?
6.1.3. People are at the center of change
6.1.4. Three elements to facilitate change
6.1.5. Eight steps to drive change

6.2. Introduction to  Lean, , an essential ingredient in any collaborative project

6.2.1. Empathy
6.2.2. History of Lean
6.2.3. Lean ein health care
6.2.4. Five Lean principles
6.2.5.  Lean Toolbox

6.3. Emotional leadership, development of skills needed to drive innovation

6.3.1.  Pull v environment vs. Push
6.3.2. What is Leadership?
6.3.3. Leadership without hierarchy
6.3.4. Hierarchical leadership traps
6.3.5. Leader 5.0.

6.4. Team Building, reinforcement dynamics in organizational transformation processes

6.4.1. The four dimensions of personality
6.4.2. Necessary personality types
6.4.3. The five dysfunctions of a team
6.4.4. The five waves of trust
6.4.5. Creating High-Performance Teams

6.5. Cultural change strategies in healthcare organizations

6.5.1. What is Management Culture?
6.5.2. Why is it relevant in a change management process?
6.5.3. Barriers
6.5.4. Hoshin Kanri
6.5.5. Examples of major organizational changes

6.6. Digital Transformation

6.6.1. Knowing and understanding the customer
6.6.2. Player: profiles: professionals, patients, institutions and medical societies and medical societies
6.6.3. Real-time information
6.6.4. Efficient, effective and certified information mapping

6.7. Educational and training strategy

6.7.1. Definition and objectives
6.7.2. Data Science
6.7.3. Living information as constantly evolving
6.7.4. Continuous training as a Medical Affairs

6.8. Content at the center

6.8.1. Content generator and manager
6.8.2. Knowing the needs of the Player
6.8.3. Create ad hoc material based on your needs
6.8.4. Reference: Based Content Quality

6.9. Measurement the implementation of the strategy

6.9.1. Definition and objectives
6.9.2. What are Assets of Cultural Interest?
6.9.3. Indicator-Based Assessment
6.9.4. Visualization as an Analysis Tool

6.10. Agile Mindset

6.10.1. What is Agile Mindset?
6.10.2. Predictive as a tool for decision making
6.10.3. Advantages and Disadvantages
6.10.4. Design of a training plan for the creation of opinion leaders

Module 7. Statistics and R

7.1. Biostatistics

7.1.1. Introduction to The Scientific Method
7.1.2. Population and Sample. Sampling Measures of Centralization
7.1.3. Discrete Distributions and Continuous Distributions
7.1.4. General Outline of Statistical Inference. Inference about a Normal Population Mean. Inference about a General Population Mean
7.1.5. Introduction to Nonparametric Inference

7.2. Introduction to R

7.2.1. Basic Features of the Program
7.2.2. Main Object Types
7.2.3. Simple Examples of Simulation and Statistical Inference
7.2.4. Graphs
7.2.5. Introduction to R Programming

7.3. Regression Methods with R

7.3.1. Regression Models
7.3.2. Variable Selection
7.3.3. Model Diagnosis
7.3.4. Treatment of Outliers
7.3.5. Regression Analysis

7.4. Multivariate Analysis with R

7.4.1. Description of Multivariate Data
7.4.2. Multivariate Distributions
7.4.3. Dimension Reduction
7.4.4. Unsupervised Classification: Cluster Analysis
7.4.5. Supervised Classification: Discriminant Analysis

7.5. Regression Methods for Research with R

7.5.1. Generalized Linear Models (GLM): Poisson Regression and Negative Binomial Regression
7.5.2. Generalized Linear Models (GLM): Logistic and Binomial Regressions
7.5.3. Poisson and Negative Binomial Regression Inflated by Zeros
7.5.4. Local Fits and Generalized Additive Models (GAMs)
7.5.5. Generalized Mixed Models (GLMM) and Generalized Additive Mixed Models (GAMM)

7.6. Statistics Applied to Biomedical Research with R I

7.6.1. Basic Notions of R. Variables and Objects in R. Data handling. Graphic files
7.6.2. Descriptive Statistics and Probability Functions
7.6.3. Programming and Functions in R
7.6.4. Contingency Table Analysis
7.6.5. Basic Inference with Continuous Variables

7.7. Statistics Applied to Biomedical Research with R II

7.7.1. Analysis of Variance
7.7.2. Correlation Analysis
7.7.3. Simple Linear Regression
7.7.4. Multiple Linear Regression
7.7.5. Logistic Regression

7.8. Statistics Applied to Biomedical Research with R III

7.8.1. Confounding Variables and Interactions
7.8.2. Construction of a Logistic Regression Model
7.8.3. Survival Analysis
7.8.4. Cox Regression
7.8.5. Predictive Models. ROC Curve Analysis

7.9. Statistical Data Mining Techniques with R I

7.9.1. Introduction. Data Mining. Supervised and Unsupervised Learning. Predictive Models. Classification and Regression
7.9.2. Descriptive Analysis Data Pre-Processing
7.9.3. Principal Component Analysis (PCA)
7.9.4. Principal Component Analysis (PCA)
7.9.5. Cluster Analysis Hierarchical Methods. K-Means

7.10. Statistical Data Mining Techniques with R II

7.10.1. Model Assessment Measures. Predictive Ability Measures. ROC Curves
7.10.2. Models Assessment Techniques. Cross-Validation. Bootstrap Samples
7.10.3. Tree-Based Methods (CART)
7.10.4. Support Vector Machines (SVM)
7.10.5. Random Forest (RF) and Neural Networks (NN)

Module 8. Professional competencies to work in  Medical Affairs

8.1. Effective public speaking

8.1.1. Ensuring the success of your presentation: overcoming stage fright. Relying on oneself to occupy all the space. Harmonizing (voice, gestures, posture, look)
8.1.2. Clearly present your ideas: organize your thinking. Define your objectives to maintain a direction. Structure your message
8.1.3. Establishing an authentic dialogue: understanding the keys to communication. Use and take advantage of the group's resources. Encourage and control public participation. How to get ideas across?
8.1.4. Make the public your ally: keep them interested with or without media. Know how to react during exchanges with improvisation. Know how to close

8.2. Managing emotions in conflict situations

8.2.1. Understanding emotions: the role of the brain. Identifying Emotions
8.2.2. Developing emotional balance: managing incoherent emotional reactions. Develop Self-confidence
8.2.3. Using emotions to build trust
8.2.4. Solve conflict situations
8.2.5. Develop Control skills

8.3. Leadership

8.3.1. Strategic planning: tools to build the vision focused on achieving the objectives. Planning as a Success Warranties
8.3.2. Decision-making: decision-making process with a clear methodology to avoid unnecessary subjectivity. Balance between reason and emotion
8.3.3. Achievement orientation: work by objectives. Tools to define objectives and their follow-up. Introduction to Servlets
8.3.4. Continuous improvement: continuous learning. The Deming Cycle

8.4. Influence and negotiation

8.4.1. Basic principles of negotiation: I actively promote collaboration to provide the best solution for my clients and colleagues
8.4.2. The Negotiation Process:. Objectives. Sides of the War of Negotiation
8.4.3. Negotiation Strategies How to approach the negotiation?
8.4.4. Communication and influence: convincing and making winning proposals

8.5. Personal Brand

8.5.1. Understanding what personal branding is: Why is it important and what does it bring us?
8.5.2. Building and managing your personal brand: five universal goals for building your personal brand. How to establish a network of contacts?
8.5.3. Social networks: choose your social networks (Linkedin, Twitter, Facebook, Instagram)
8.5.4. Launching your personal brand: personal branding campaigns and how to measure success

8.6. Adaptation to Change

8.6.1. Accepting change: this is the phase of understanding the need for change, when people are stabilized and accept the new situation
8.6.2. Resistance to change: knowing how to identify the barriers and difficulties that position people against change is a way to find solutions that help to incorporate new ways of doing things
8.6.3. Process of Change. The hero's journey: understanding the process of change from denial to transformation of individuals
8.6.4. Change management in organizations: understanding Kotter-like models of change management in organizations

8.7. Problem Solving

8.7.1. Understanding of the problem: understanding the problem, identifying its causes and the challenges it presents
8.7.2. Idea generation: ideation and creativity processes to develop different solutions
8.7.3. Analysis: idea analysis models
8.7.4. Decision-making: tools for decision making

8.8. Team Management

8.8.1. Functional teams: achievement-oriented teams. Lencioni Pyramid
8.8.2. Tools for Interdisciplinary Team Management
8.8.3. Motivation techniques: models for motivating team members. Intrinsic and Motivation Extrinsic Motivation
8.8.4. Feedback:  reinforce the employees' sense of responsibility in the development of the company's work

8.9. Professional efficiency Time Management

8.9.1. The time paradigm: understanding the relative importance of time
8.9.2. Personal efficiency: be a strategist of your time and focus on what is really important to improve your productivity
8.9.3. Time management tools and techniques: stress management, time management tools and methods

8.10. Job Placement

8.10.1. Setting your career goal: tools to define your career goal
8.10.2. CV preparation: identification of professional skills and competencies for CV preparation
8.10.3. Job search: job search techniques. Networking, social networks, search engines and Head Hunters
8.10.4. The Interview How to face a job interview?

Module 9. Clinical Practice Guidelines. Real Word Evidence. Critical Reading of Articles

9.1. Introduction to Evidence-Based Clinical Practice Scientific

9.1.1. Health technology assessment. GPC Framework
9.1.2. Evidence-Based GPC Medicine Methodological Approach
9.1.3. Key Aspects in the GPC Production
9.1.4. From evidence to recommendations

9.2. Clinical practice guideline quality assessment tool

9.2.1. Evaluation of GPC: Why and What For?
9.2.2. AGREE Collaboration
9.2.3. AGREE instrument: structure and content
9.2.4. Examples of CPG evaluation with the AGREE instrument

9.3. Sources of quality of evidence-based clinical practice guidelines

9.3.1. Quality CPG compiling agencies
9.3.2. GuiaSalud: national evidence-based quality CPG program
9.3.3. Centers that produce quality CPGs
9.3.4. Methodological centers: GIN international network
9.3.5. MySQL Database
9.3.6. Search Engines

9.4. Incorporation of patients in clinical practice guidelines

9.4.1. Necessity of Patient Incorporation-Up
9.4.2. Aspects Methodology to Consider
9.4.3. Examples of patient participation in CPGs
9.4.4. International approach: Patient Involvement

9.5. Decision Support Tools share

9.5.1. The need for shared decision support tools
9.5.2. Conceptual Principles
9.5.3. Practical Examples

9.6. Real-world Evidence

9.6.1. Need to generate new evidence
9.6.2. Studies based on real clinical practice data: design, analysis, minimization of bias
9.6.3. IA as tools for the generation of evidence
9.6.4. AI-based advances for healthcare interventions

9.7. The importance of critical reading, methodology and structure

9.7.1. Levels of scientific evidence
9.7.2. Intervention
9.7.3. Methods to be used
9.7.4. Types of Studies

9.8. Clinical Research and Trials

9.8.1. Hypothesis Testing
9.8.2. Power of the study
9.8.3. Types of and Tests Variables
9.8.4. Types of Trials
9.8.5. Types of Intervention: Intention-to-treat o Per-protocol
9.8.6. Non-inferiority
9.8.7. Biases

9.9. Systematic Reviews and Meta-Analyses

9.9.1. Systematic Reviews
9.9.2. Meta-Analysis

9.10. Electronic medical education

9.10.1. Drug Information Sources
9.10.2. Blogs, infographics, podcasts
9.10.3. Medical education portals
9.10.4. Virtual congresses
9.10.5. Webinars and Webcasts, eMSL, eKOL

Module 10. Medical Information

10.1. Introduction. Organization of the search process

10.1.1. Research Question What is it for?
10.1.2. Objectives of the Search
10.1.3. Bibliographic/material/human resources at our disposal

10.2. Biomedical information resources

10.2.1. International sources: Pubmed, Embase, WOS, etc
10.2.2. Sources in Latin America: CSIC, Ibecs, LILACS, etc. indexes
10.2.3. Sources for locating clinical trials: WHO, ClinicalTrials, Cochrane CENTRAL, etc
10.2.4. Drug Information Sources: Bot Plus Web, FDA, etc
10.2.5. Evidence: Based Medicine. Uptodate, iloveevidence, Tripdatabase
10.2.6. Other resources: official organizations, web pages, scientific societies, associations, evaluation agencies, etc

10.3. Databases. Basic concepts for quality search strategies

10.3.1. What is Database?
10.3.2. Natural language. Mapping of terms
10.3.3. Controlled language. Thesauri
10.3.4. Boolean Operations

10.4. Bibliographic searches in Pubmed

10.4.1. Simple search and exploratory search
10.4.2. Mapping of terms
10.4.3. Advanced Search
10.4.4. Keys to search
10.4.5. Search strategy and results management. Alerts Bibliographic Reference Management Systems

10.5. Procurement Documentation Adaptation to other databases

10.5.1. Information needed to document and make the search replicable
10.5.2. Transparency and quality
10.5.3. Points to consider when adapting the search from one database to others
10.5.4. Peer review of searches
10.5.5. Updating the search strategy

10.6. Medical information for the patient

10.6.1. How to communicate to the patient?
10.6.2. Verbal and Written Communication
10.6.3. The leaflet as a basis for patient feedback

10.7. Medical information for HCP

10.7.1. How to communicate to the healthcare professional?
10.7.2. Verbal and Written Communication
10.7.3. The technical data sheet as a basis for response to the healthcare professional

10.8. Medical information Off-Label

10.8.1. Definition and Basic Concepts
10.8.2. Data On File
10.8.3. Foreign medication
10.8.4. Clinical trials, Early Access and access to medicines in special situations in special situations

10.9. Scientific documentation and information for Medical Affairs

10.9.1. Management of scientific documentation requests for the healthcare professional: transfers of value and local regulation
10.9.2. Safeguard copyrights
10.9.3. Medical information as a strategy for updating the medical team
10.9.4. Medical information in the identification of Data Gaps

10.10. Data extraction and Insights analysis

10.10.1. Medical Insights: definition and concepts
10.10.2. Medical information query management tools
10.10.3  Data Storage: Data Privacy
10.10.4  Data Mining

The Relearning system used by TECH will allow you to considerably reduce the hours of study and memorization”